LY4100511 (DC-853)

DRUG3 trials

Sponsors

DICE Therapeutics, Inc., a wholly owned subsidiary of Eli Lilly and Company

Conditions

Healthy

Phase 1

A Study to Evaluate Safety, Tolerability of LY4100511 (DC-853) in Healthy Asian and Non-Asian Participants

CompletedNCT06311656

DICE Therapeutics, Inc., a wholly owned subsidiary of Eli Lilly and CompanyHealthy

Start: 2024-03-19End: 2024-10-04Updated: 2025-02-24

A Study to Assess LY4100511 (DC-853) in Healthy Adult Participants

CompletedNCT06345794

DICE Therapeutics, Inc., a wholly owned subsidiary of Eli Lilly and CompanyHealthy

Start: 2024-04-03End: 2024-06-18Updated: 2025-04-27

A Study of LY4100511 (DC-853) Mass Balance and Absolute Bioavailability of LY4100511 in Healthy Male Participants

CompletedNCT06627088

DICE Therapeutics, Inc., a wholly owned subsidiary of Eli Lilly and CompanyHealthy

Start: 2024-08-23End: 2024-12-31Updated: 2025-01-24